Shares of Dynavax Technologies shot up 31 percent in after-hours trading after the developer announced that a late-stage trial of its experimental vaccine for hepatitis B showed that it performed better after two doses than three doses of GlaxoSmithKline's vaccine. Two doses of Hepislav protected 98 percent of volunteers compared to 25 percent protected by two doses of Glaxo's Engerix-B. Analysts say the data shows that Dynavax can successfully compete against Glaxo in the $1 billion hepatitis B market. Glaxo's vaccine is dominant, with $450 million in annual sales.
- check out the release on the trial data
- here's the AP report